As main protein-carriers, Hcs are widely used for TACA-based cancer vaccine constructions in several tumor models and clinical trials: Globo-H-KLH conjugate vaccine for breast cancer [35]; Globo-H-GM2-sTn-TF-Tn-KLH conjugate vaccine for ovarian cancer [36]; and GM2-KLH conjugate for melanoma treatment [37]. Here, TF is linked to breast carcinoma.